Skip to main content

Table 1 Age, sex and medication of the patients with psoriatic arthritis (PsA) at baseline (BL) and the 12- months (M12) and 24-months (M24) visits

From: Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up

  BL
(N = 39)
M12
(N = 39)
M24
(N = 35)
Women, n(%)   25 (64.1) 21 (60.0)
Men, n(%)   14 (35.9) 14 (40.0)
Age, years (IQR)   56 (49–63) 59 (51–56)
NSAIDs, n (%) 27 (69.2) 25 (64.1) 21 (60.0)
TNFi all, n (%) 15 (38.5) 16 (41.0) 14 (40.0)
TNFi in monotherapy 4 (10.3) 4 (10.3) 3 (8.6)
TNFi + csDMARD 11 (28.2) 12 (30.7) 11 (31.4)
Ustekinumab monotherapy, n (%) 1 (2.6) 0 0
Secukinumab monotherapy, n (%) 0 1 (2.6) 2 (5.7)
csDMARD without biologic, n (%) 17 (43.6) 16 (41.0) 14 (40.0)
Methotrexate 11 (28.2) 11 (28.3) 10 (28.6)
Sulfasalazine 2 (5.1) 1 (2.6) 1 (2.9)
Apremilast 1 (2.6) 1 (2.6) 2 (5.7)
Methotrexate + Sulfasalazine 3 (7.7) 3 (7.7) 1 (2.9)
Prednisolone, n (%) 3 (7.7) 2 (5.1) 2 (5.7)
Anti-hypertensives, n (%) 17 (43.6) 14 (35.9) 14 (40.0)
Lipid lowering therapy, n (%) 6 (15.4) 5 (12.8) 5 (14.3)
Oral anti-diabetics, n (%) 1 (2.6) 2 (5.1) 2 (5.7)
Allopurinol, n (%) 2 (5.1) 2 (5.1) 2 (5.7)
  1. csDMARD = conventional synthetic Disease Modifying Anti-Rheumatic Drug, IQR = inter-quartile range, NSAID = non-steroidal anti-inflammatory drug, TNFi = tumor necrosis factor inhibitor